Skip to main content

Sensei Biotherapeutics, Inc.

corporate_fare Company Profile

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed SNSE - Latest Insights

SNSE
Apr 28, 2026, 7:24 AM EDT
Filing Type: S-3
Importance Score:
9
SNSE
Apr 27, 2026, 4:20 PM EDT
Filing Type: DEFA14A
Importance Score:
9
SNSE
Apr 27, 2026, 4:19 PM EDT
Filing Type: DEF 14A
Importance Score:
9
SNSE
Apr 16, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
SNSE
Apr 16, 2026, 4:01 PM EDT
Filing Type: PRE 14A
Importance Score:
9
SNSE
Apr 15, 2026, 4:15 PM EDT
Filing Type: 8-K/A
Importance Score:
9
SNSE
Mar 30, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
10
SNSE
Mar 30, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
SNSE
Feb 24, 2026, 4:11 PM EST
Filing Type: 144
Importance Score:
8
SNSE
Feb 18, 2026, 8:45 AM EST
Filing Type: 8-K
Importance Score:
10
SNSE
Feb 13, 2026, 5:29 PM EST
Filing Type: 8-K
Importance Score:
7